

Amendments to the Claims:

The following listing of claims replaces all prior listings, and all prior versions, of claims in the application.

Listing of Claims:

1. (Currently Amended) A ~~preventive or~~ therapeutic agent for decubitus, which comprises, as active agent for treating the decubitus, an N-acylated derivative of hydroxyproline or a salt thereof, in an effective amount for therapeutically treating decubitus.

2. (Currently Amended) The ~~preventive or~~ therapeutic agent for decubitus according to claim 1, wherein the N-acylated derivative of hydroxyproline or a salt thereof is contained in an amount of 0.1 to 15% by weight to the total weight.

3. (Currently Amended) The ~~preventive or~~ therapeutic agent for decubitus according to claim 1 or 2, wherein an acyl group of the N-acylated derivative of hydroxyproline is the acyl group having 1 to 24 carbon atoms.

4.-6. (Cancelled)

7. (Currently Amended) A method of ~~preventing or~~ treating decubitus, which comprises administering a composition comprising an N-acylated derivative of hydroxyproline or a salt thereof, as an active agent, to an animal or human being suffering from decubitus, in an effective amount to therapeutically treat the decubitus.

8. (Currently Amended) The method of ~~preventing or~~ treating decubitus according to claim 7, wherein the composition contains 0.1 to 15% by weight of the N-acylated derivative of hydroxyproline or a salt thereof to the total weight.

9. (Currently Amended) The method of ~~preventing or~~ treating decubitus according to claim 7 or 8, wherein the acyl group of N-acylated derivative of hydroxyproline is the acyl group having 1 to 24 carbon atoms.

10. (New) A method of manufacturing a therapeutic agent for decubitus, comprising incorporating in said therapeutic agent an N-acylated derivative of hydroxyproline or a salt thereof as an active agent of said therapeutic agent, said N-acylated derivative of hydroxyproline or salt thereof being incorporated in an effective amount for therapeutically treating the decubitus.

11. (New) The method according to claim 10, wherein the N-acylated derivative of hydroxyproline or a salt thereof is incorporated in said therapeutic agent in an amount of 0.1 to 15% by weight to the total weight.

12. (New) The method according to claim 10 or 11, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.

13. (New) An agent for prevention of decubitus, which comprises, as an active agent for prevention of decubitus, an N-acylated derivative of hydroxyproline or a salt thereof, in an effective amount for prevention of decubitus.

14. (New) The agent for prevention of decubitus according to claim 13, wherein the N-acylated derivative of hydroxyproline or a salt thereof is incorporated in said agent for prevention of decubitus in an amount of 0.1 to 15% by weight to the total weight.

15. (New) The agent for prevention of decubitus according to claim 13 or 14, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.

16. (New) A method of prevention of decubitus, which comprises administering a composition comprising an N-acylated derivative of hydroxyproline or a salt thereof to an animal or human being, the N-acylated derivative of hydroxyproline or a salt thereof being included in the composition in an effective amount for prevention of decubitus.

17. (New) The method according to claim 16, wherein the N-acylated derivative of hydroxyproline or a salt thereof is incorporated in said composition in an amount of 0.1 to 15% by weight to the total weight.

18. (New) The method according to claim 16 or 17, wherein the acyl group of the N-acylated derivative of hydroxyproline is an acyl group having 1 to 24 carbon atoms.